18F-AV-1451与脑脊液tau蛋白诊断阿尔茨海默病的比较
该研究比较了18F-AV-1451 PET显像与脑脊液总tau(t-tau)和磷酸化tau(p-tau)对阿尔茨海默病(AD)的诊断性能,纳入30例对照、14例前驱期AD和39例AD痴呆患者。结果显示,18F-AV-1451在AD痴呆期诊断性能接近完美(AUROC约1.000),显著优于脑脊液tau和MRI指标;在前驱期AD,脑脊液tau与18F-AV-1451诊断性能无显著差异。
要点
- 18F-AV-1451 PET对AD痴呆诊断性能极高,AUROC约1.000。
- 前驱期AD中,脑脊液tau与18F-AV-1451 PET诊断性能相当。
- 在AD痴呆期,18F-AV-1451 PET显著优于脑脊液tau和MRI指标。
核心结论
- 脑脊液tau与18F-AV-1451在AD早期临床阶段性能相当,但18F-AV-1451在痴呆阶段更优,对轻中度AD诊断性能接近完美。
研究设计与样本
- 研究纳入来自瑞典BioFINDER研究的30例对照、14例前驱期AD和39例AD痴呆患者,比较t-tau、p-tau与18F-AV-1451 PET的诊断性能。
主要发现
- 18F-AV-1451滞留值在AD痴呆期显著升高,在前驱期AD中度升高。
- 脑脊液t-tau和p-tau在AD痴呆和前驱期AD均升高至相似水平。
- 18F-AV-1451对AD痴呆的AUROC约1.000,显著优于t-tau(0.876)、p-tau(0.890)、海马体积(0.824)和颞叶皮层厚度(0.860)。
- 前驱期AD中,脑脊液tau与18F-AV-1451的AUROC无显著差异(0.836-0.939),但MRI指标AUROC较低(0.652-0.769)。
关键数值与推荐
- 18F-AV-1451对AD痴呆的AUROC约1.000,t-tau为0.876,p-tau为0.890,海马体积为0.824,颞叶皮层厚度为0.860。
- 前驱期AD中,脑脊液tau与18F-AV-1451的AUROC范围为0.836-0.939,MRI指标AUROC范围为0.652-0.769。
临床怎么用
- 在AD痴呆期,18F-AV-1451 PET可作为优于脑脊液tau和MRI的影像学诊断工具。
- 在前驱期AD,脑脊液tau与18F-AV-1451 PET诊断性能相当,可根据临床可及性选择。
局限性
- 研究样本量有限(共83例),需更大样本验证。
- 所有AD患者均经脑脊液β-淀粉样蛋白42筛查为淀粉样蛋白阳性,可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare PET imaging of tau pathology with CSF measurements (total tau [t-tau] and phosphorylated tau [p-tau]) in terms of diagnostic performance for Alzheimer disease (AD). METHODS: We compared t-tau and p-tau and 18F-AV-1451 in 30 controls, 14 patients with prodromal AD, and 39 patients with Alzheimer dementia, recruited from the Swedish BioFINDER study. All patients with AD (prodromal and dementia) were screened for amyloid positivity using CSF β-amyloid 42. Retention of 18F-AV-1451 was measured in a priori specified regions, selected for known associations with tau pathology in AD. RESULTS: Retention of 18F-AV-1451 was markedly elevated in Alzheimer dementia and moderately elevated in prodromal AD. CSF t-tau and p-tau was increased to similar levels in both AD dementia and prodromal AD. 18F-AV-1451 had very good diagnostic performance for Alzheimer dementia (area under the receiver operating characteristic curve [AUROC] ∼1.000), and was significantly better than t-tau (0.876), p-tau (0.890), hippocampal volume (0.824), and temporal cortical thickness (0.860). For prodromal AD, there were no significant AUROC differences between CSF tau and 18F-AV-1451 measures (0.836-0.939), but MRI measures had lower AUROCs (0.652-0.769). CONCLUSIONS: CSF tau and 18F-AV-1451 have equal performance in early clinical stages of AD, but 18F-AV-1451 is superior in the dementia stage, and exhibits close to perfect diagnostic performance for mild to moderate AD. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that CSF tau and 18F-AV-1451 PET have similar performance in identifying early AD, and that 18F-AV-1451 PET is superior to CSF tau in identifying mild to moderate AD.
引用
- Mattsson N, Smith R, Strandberg O, et al. Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology. 2018. PMID: 29321235. doi:10.1212/WNL.0000000000004887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。